MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 591499 | Name: Amfenac sodium
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Amfenac, also known as 2-amino-3-benzoylbenzeneacetic acid, is a nonsteroidal anti-inflammatory drug (NSAID) with acetic acid moiety.

Chemical Structure

Amfenac sodium
Amfenac sodium
CAS#61941-56-8 (sodium)

Theoretical Analysis

MedKoo Cat#: 591499

Name: Amfenac sodium

CAS#: 61941-56-8 (sodium)

Chemical Formula: C15H12NNaO3

Exact Mass: 277.0715

Molecular Weight: 277.26

Elemental Analysis: C, 64.98; H, 4.36; N, 5.05; Na, 8.29; O, 17.31

Price and Availability

Size Price Availability Quantity
1g USD 250.00 2 Weeks
2g USD 350.00 2 Weeks
5g USD 650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
61618-27-7 (sodium hydrate) 61941-56-8 (sodium) 51579-82-9 (free)
Synonym
Amfenac sodium; AHR 5850; AHR5850; AHR5850
IUPAC/Chemical Name
Benzeneacetic acid, 2-amino-3-benzoyl-, monosodium salt
InChi Key
MJAQSCHBMPGJES-UHFFFAOYSA-M
InChi Code
InChI=1S/C15H13NO3.Na/c16-14-11(9-13(17)18)7-4-8-12(14)15(19)10-5-2-1-3-6-10;/h1-8H,9,16H2,(H,17,18);/q;+1/p-1
SMILES Code
O=C([O-])CC1=CC=CC(C(C2=CC=CC=C2)=O)=C1N.[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 277.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sheppard JD, Cockrum PC, Justice A, Jasek MC. In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits. Ophthalmol Ther. 2018 May 14. doi: 10.1007/s40123-018-0130-1. [Epub ahead of print] PubMed PMID: 29761367. 2: Acar U, Acar DE, Tanriverdi C, Acar M, Ozdemir O, Erikci A, Ornek F. Prostaglandin E(2) Levels of Aqueous and Vitreous Humor in Ketorolac 0.4% and Nepafenac 0.1% Administered Healthy Rabbits. Ocul Immunol Inflamm. 2017 Jun;25(3):323-327. doi: 10.3109/09273948.2015.1116587. Epub 2016 Jan 14. PubMed PMID: 26765265. 3: Chastain JE, Sanders ME, Curtis MA, Chemuturi NV, Gadd ME, Kapin MA, Markwardt KL, Dahlin DC. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye. Exp Eye Res. 2016 Apr;145:58-67. doi: 10.1016/j.exer.2015.10.009. Epub 2015 Oct 22. PubMed PMID: 26474497. 4: Kida T, Kozai S, Takahashi H, Isaka M, Tokushige H, Sakamoto T. Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. PLoS One. 2014 May 5;9(5):e96481. doi: 10.1371/journal.pone.0096481. eCollection 2014. PubMed PMID: 24796327; PubMed Central PMCID: PMC4010472. 5: Bucolo C, Marrazzo G, Platania CB, Romano GL, Drago F, Salomone S. Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation. J Pharm Pharmacol. 2014 Jul;66(7):954-60. doi: 10.1111/jphp.12224. Epub 2014 Feb 12. PubMed PMID: 24697218. 6: Argun M, Tök L, Uğuz AC, Çelik Ö, Tök ÖY, Naziroğlu M. Melatonin and amfenac modulate calcium entry, apoptosis, and oxidative stress in ARPE-19 cell culture exposed to blue light irradiation (405 nm). Eye (Lond). 2014 Jun;28(6):752-60. doi: 10.1038/eye.2014.50. Epub 2014 Mar 7. PubMed PMID: 24603419; PubMed Central PMCID: PMC4058615. 7: Jones BM, Neville MW. Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery. Ann Pharmacother. 2013 Jun;47(6):892-6. doi: 10.1345/aph.1R757. Epub 2013 May 28. Review. PubMed PMID: 23715071. 8: Carreño E, Portero A, Galarreta DJ, Herreras JM. Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction. Clin Ophthalmol. 2012;6:637-44. doi: 10.2147/OPTH.S23381. Epub 2012 Apr 27. PubMed PMID: 22570544; PubMed Central PMCID: PMC3346189. 9: Bucci FA Jr, Waterbury LD. A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. Curr Med Res Opin. 2011 Dec;27(12):2235-9. doi: 10.1185/03007995.2011.626018. Epub 2011 Oct 12. PubMed PMID: 21992076. 10: Haketa T, Kino K, Sugisaki M, Takaoka M, Ohta T. Randomized clinical trial of treatment for TMJ disc displacement. J Dent Res. 2010 Nov;89(11):1259-63. doi: 10.1177/0022034510378424. Epub 2010 Aug 25. PubMed PMID: 20739691. 11: Heier JS, Awh CC, Busbee BG, Waterbury LD, Daniel P, Stoller GL, Cleary TS. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Retina. 2009 Oct;29(9):1310-3. doi: 10.1097/IAE.0b013e3181b094e6. PubMed PMID: 19934822. 12: Yanni SE, Clark ML, Yang R, Bingaman DP, Penn JS. The effects of nepafenac and amfenac on retinal angiogenesis. Brain Res Bull. 2010 Feb 15;81(2-3):310-9. doi: 10.1016/j.brainresbull.2009.10.018. Epub 2009 Nov 6. PubMed PMID: 19897019; PubMed Central PMCID: PMC2815002. 13: Lal N, Kumar J, Erdahl WE, Pfeiffer DR, Gadd ME, Graff G, Yanni JM. Differential effects of non-steroidal anti-inflammatory drugs on mitochondrial dysfunction during oxidative stress. Arch Biochem Biophys. 2009 Oct 1;490(1):1-8. PubMed PMID: 19810214. 14: Bucci FA Jr, Waterbury LD. Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2008 Aug;34(8):1226; author reply 1226-7. doi: 10.1016/j.jcrs.2008.05.019. PubMed PMID: 18655957. 15: Gaynes BI, Onyekwuluje A. Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension. Clin Ophthalmol. 2008 Jun;2(2):355-68. PubMed PMID: 19668727; PubMed Central PMCID: PMC2693998. 16: Fernandes BF, Marshall JC, Di Cesare S, Logan P, Maloney S, Burnier MN Jr. Amfenac increases the radiosensitivity of uveal melanoma cell lines. Eye (Lond). 2008 May;22(5):701-6. Epub 2007 Nov 30. PubMed PMID: 18049486. 17: Marshall JC, Caissie AL, Cruess SR, Cools-Lartigue J, Burnier MN Jr. The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production. J Carcinog. 2007 Nov 27;6:17. PubMed PMID: 18042295; PubMed Central PMCID: PMC2222223. 18: Walters T, Raizman M, Ernest P, Gayton J, Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007 Sep;33(9):1539-45. PubMed PMID: 17720067. 19: Bucci FA Jr, Waterbury LD, Amico LM. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification. Am J Ophthalmol. 2007 Jul;144(1):146-7. PubMed PMID: 17601444. 20: Acosta MC, Luna C, Graff G, Meseguer VM, Viana F, Gallar J, Belmonte C. Comparative effects of the nonsteroidal anti-inflammatory drug nepafenac on corneal sensory nerve fibers responding to chemical irritation. Invest Ophthalmol Vis Sci. 2007 Jan;48(1):182-8. PubMed PMID: 17197531.